Best Genomics Companies in Switzerland
The 94 best Genomics companies in Switzerland in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Syngenta.
Switzerland's Genomics sector earns its own ranking here: 94 companies tracked, $784M in disclosed funding, and a field that's moving fast enough to watch quarter by quarter. The global market sat at roughly $24.3B in 2021 and is forecast to reach $85.1B by 2030 at a 16.37% CAGR, driven by falling sequencing costs, government backing, and accelerating demand for personalized medicine. Syngenta leads our directory at $250M raised. CRISPR Therapeutics follows at $127M. The gap between those two and the rest of the pack is wide, which tells you something about where capital has concentrated.
Hot themes right now are pharmacogenomics, machine learning drug discovery, and hereditary disease applications. I'd flag that Mukesh Ambani recently called genomics one of the forces shaping the next era of growth, which signals how mainstream the sector conversation has become. And as shown in 2011 research, sequencing technology's trajectory was always pointing toward clinical integration. Switzerland's ecosystem, backed by investors like Venture Kick and MassChallenge, is positioned right at that intersection. So if you're scanning for where the next funding rounds surface, this is the list to watch.
- Genomics Market Surges with PCR and AI Technologies Projected to Reach
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Switzerland
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Syngenta Developer of technologies and sustainable farming practices for farmers | $250M | 37 mo ago | 501 | Jon Fyrwald CEO | StoreHippoApple iCloud MailNode.js+25 | Top 500k | 1,334 patents Genetically engineered crops: haploid induction, flowering control, and disease resistance traits. | — |
| 2 | CRISPR Therapeutics Developer of solutions for treating human genetic diseases by using genome editing technology | $127M | 30 mo ago | 458 | — | DrupalApple iCloud MailPHP+21 | Top 5M | 912 patents CRISPR genome editing for engineered universal donor cells and cancer immunotherapy | — |
| 3 | Anjarium Biosciences Developer of next generation non-viral gene therapies | $60M | 57 mo ago | 38 | — | — | — | 63 patents Nanovesicle drug delivery systems and recombinant DNA therapeutic production | — |
| 4 | TOLREMO therapeutics Developing anti-cancer small molecules targeting novel drug resistance pathways | $56M | 33 mo ago | 16 | Karl-Heinz Altmann Co-Founder | Squarespace CommerceSquarespaceTypeScript+14 | Top 50M | 71 patents Patents concentrated in health & consumer products | 1 job opening |
| 5 | NewBiologix Provider of engineered cell lines for drug development | $50M | 37 mo ago | — | Nicolas Mermod Co-Founder | — | — | — | — |
| 6 | BC Platforms Provider of a platforms for genomic data analysis and management | $47M | 41 mo ago | 17 | — | WordPressMySQLPHP+23 | Top 10M | — | — |
| 7 | NimbleGen NGS solutions for research applications | $31M | 227 mo ago | 135 | Rebecca Selzer ex-President & CEO | — | — | — | — |
| 8 | HAYA Therapeutics Developer of RNA-based therapies for treating heart diseases | $25M | 13 mo ago | 38 | Samir Ounzain Co-Founder & CEO | WordPressMySQLPHP+18 | Top 10M | 18 patents RNA‑based therapeutics targeting noncoding RNAs, super‑enhancers, and transposable elements for disease modulation | — |
| 9 | Lumavita Developer of small molecule therapeutics for gynecological infections | $22M | 204 mo ago | — | Cees Winnips Co-Founder & CSO | — | — | 22 patents High-purity pentamycin antibiotic purification and formulation processes | — |
| 10 | Scailyte Artificial intelligence (AI) based single-cell data analysis for novel biomarker discovery | $20M | 30 mo ago | 28 | Peter Nestorov Co-Founder and CEO | Framer SitesReactPriority Hints+5 | Top 50M | 11 patents Diagnostic biomarkers for female reproductive tract diseases and immune‑related cancers | — |
| 11 | Novigenix Developer of technology for cancer precision medicine | $20M | 14 mo ago | 28 | — | WordPressMySQLPHP+25 | Top 50M | 20 patents Predictive biomarkers and assays for cancer immunotherapy response and colorectal neoplasia detection | — |
| 12 | InnoMedica Developer of therapeutics to treat cancer | $10M | 95 mo ago | 41 | — | WordPress Block EditorWordPressMySQL+7 | Top 10M | — | — |
| 13 | GenomSys Provider of solutions and systems for efficient genomic information processing | $9M | 81 mo ago | 20 | — | WordPress Block EditorwpBakeryWordPress+22 | Top 50M | 199 patents Efficient compression, storage, indexing, and retrieval of large genomic sequence data. | 1 partnership |
| 14 | Artidis Provider of nanotechnology tool for cancer diagnosis | $9M | 78 mo ago | 4 | Marija Plodinec Co-Founder & Chief Executive Officer | WordPressApple iCloud MailMicrosoft 365+24 | Top 10M | 21 patents Nanomechanical tissue analysis via atomic force microscopy for cancer diagnostic and treatment prediction | — |
| 15 | Navignostics Developer of personalized diagnostics for cancer patients | $8M | 45 mo ago | 8 | Jana Fischer Co-Founder | WordPressMySQLPHP+19 | Top 50M | — | — |
| 16 | Rqmicro Developer of instruments, reagents, and kits for rapid pathogen detection | $6M | 62 mo ago | 14 | Hans-Anton Keserue Founder & CEO | — | — | 18 patents Patents concentrated in transport & manufacturing processes | — |
| 17 | Mybacs Manufacturer of probiotic products for digestion | $6M | 31 mo ago | 27 | Adrian Weingart Co-Founder | Cart FunctionalityShopifySentry+46 | Top 1M | — | 2 job openings · 1 launch |
| 18 | Embion Technologies Developer of a synthetic biology platform for converting waste into useful chemicals for industrial uses | $5M | 54 mo ago | 13 | — | — | — | — | — |
| 19 | AlitheaGenomics Provider of transcriptomics solutions for research and biomarker discovery 37Talent top 38%Funding top 42%Tech top 42%News top 43% All 8 signals ▾Talenttop 38% Fundingtop 42% Techtop 42% Newstop 43% Growthtop 45% Moattop 48% Globalbottom 39% Marketbottom 26% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $4.2M across 6 rounds · 6 rounds over 6 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $4M | 3 mo ago | 9 | Daniel Alpern Co-Founder | WordPressApple iCloud MailMicrosoft 365+30 | Top 5M | — | 2 launchs · 1 partnership |
| 20 | SwissDeCode Provider of disposable DNA Kit for detection of food contaminants | $4M | 56 mo ago | 14 | Brij Sahi Chairman and Co-Founder | — | — | 6 patents Food safety certification and agricultural product testing systems | 1 partnership |
| 21 | PreComb Provides functional cancer profiling using biomarker analysis | $4M | 17 mo ago | 11 | Jens Kelm Co-Founder | WordPressMySQLPHP+22 | Top 50M | — | — |
| 22 | Swiss Nuclides Developer of radionuclide PET tracers for precision diagnostics | $3M | 60 mo ago | — | Gustav Schulthess Co-Founder | — | — | — | 1 launch |
| 23 | Oncobit Developer of diagnostic and monitoring tests for precision treatment | $3M | 6 mo ago | 13 | Claudia Scheckel CEO | — | — | 2 patents Detecting specific DNA/RNA mutations in clinical samples using computational analysis | 1 launch |
| 24 | Saphetor Developer of platform for automated next-gen sequencing analysis | $1M | 124 mo ago | 70 | — | WebflowMicrosoft AdvertisingjQuery+10 | Top 50M | — | — |
| 25 | ChemAlive Cloud-based computational platform for chemical research | $808K | 101 mo ago | 2 | — | — | — | — | — |
| 26 | 3Brain High resolution MicroElectrode Array (#MEA) platform to study #Brain and #retinal disorders ( #Alzheimer's… | $649K | 65 mo ago | 34 | — | Webflow EcommerceWebflowApple iCloud Mail+22 | Top 10M | 17 patents High‑throughput cellular assay platforms using probe array bio‑sensing technologies | — |
| 27 | Karmagenes Genetic test for providing behavioral insights | $272K | 122 mo ago | 2 | Samer Yammine Managing Partner | — | — | — | — |
| 28 | Genknowme Developer of AI-based epigenetic testing platform | $152K | 75 mo ago | 10 | — | — | — | 4 patents Quantitative assessment of biological age and allostatic load for health analytics | 1 partnership |
| 29 | CEIDOS Provider of cell culturing devices for patients cells modification | $150K | 51 mo ago | 8 | Leonard Barras Co-Founder | — | — | 16 patents Real-time cell culture monitoring using dielectrophoretic analysis | — |
| 30 | CellSpring Developer of minimally invasive tests to diagnose early stage cancer | $142K | 79 mo ago | — | Kramer Schmidt Co-Founder & CEO | — | — | — | — |
| 31 | Lucentix Developer of sensors for home-based blood testing | $131K | 132 mo ago | — | Rudolf Griss Co-Founder & CEO | — | — | — | — |
| 32 | BioCopy Developer of immunotherapies for tumor and autoimmune diseases | $116K | 92 mo ago | 27 | Niko Bausch Co-Founder | Node.jsReactNext.js App Router+9 | Top 50M | — | — |
| 33 | Pattern Biosciences Developer of programmable gene therapies for cancer treatment | $114K | 83 mo ago | 8 | Bartolomeo Angelici VP Discovery Research | WebflowLenisjQuery+11 | Top 50M | — | — |
| 34 | Synthena Developer of antisense therapeutics based on proprietary oligo platform to treat DMD | $111K | 77 mo ago | — | Luc Pettavino Co-CEO | — | — | 33 patents Synthetic tricyclo‑DNA oligonucleotide therapeutics for gene‑editing and rare disease treatment | — |
| 35 | Amphasys Developer of label-free technology for pollen viability analysis | $109K | 72 mo ago | 20 | Marcel Ottiger Co-Founder | WordPressMySQLPHP+31 | Top 50M | 8 patents Pollen viability grading and milk cell‑load detection using optical/fluorescence analytical methods | — |
Top 12 Genomics companies in Switzerland
#1
Seed · Lausanne, Vaud · founded 2020 · 9 employees$4.2Mraised▾
Provider of transcriptomics solutions for research and biomarker discovery. The company offers proprietary technology for RNA-seq of multiplex RNA samples for sequencing. The company also offers mRNA sequencing services and a kit that can be used for multiple samples.
- Mar 2026Seed$3.9M
- Mar 2024Seed$3.2M
- Mar 2023Conventional Debt$539.1K
- May 2022Seed$1M
#2
Series A · Lausanne, Vaud · founded 2017 · 38 employees$25Mraised▾
Developer of RNA-based therapies for treating heart diseases. It offers a platform that integrates multimodal functional genomics with computational tools to determine RNA-targeting modalities, such as modified antisense oligonucleotides (ASOs) to inhibit lncRNAs to prevent Fibrosis.
- May 2025Series A$65M
- Feb 2022Seed$5M
- May 2021Seed$20M
- Nov 2017Grant (prize money)$40.3K
#3
Series A · Zurich, Zurich · founded 2018 · 13 employees$2.5Mraised▾
Developer of diagnostic and monitoring tests for precision treatment. The products OncobitDx for precise diagnosis, OncobitLB for monitoring, and OncobitPM for identification of recurrence of cancer. The company uses bioinformatic analysis and data interpretation and provides results and therapy-decision for cancer treatment.
- Dec 2025Series A$2.4M
- Nov 2024Seed$1.7M
- Apr 2021Seed$2.5M
#4
Series B · Epalinges, Vaud · founded 2014 · 28 employees$20Mraised▾
Developer of technology for cancer precision medicine. It offers an Immuno-transcriptomic platform combined with machine learning and predictive algorithms that enables the identification of disease-specific mRNA signatures of immune cells and the progression of the disease. Its lead product, Colox a molecular test that measures the immune system's reaction to colorectal cancer.
- Apr 2025Grant (prize money)$2M
- Nov 2022Series B$20M
- Jan 2020Grant (prize money)$1.1M
#5
Public · Basel, Basel Stadt · founded 2013 · 458 employees$127Mraised▾
Developer of solutions for treating human genetic diseases by using genome editing technology. It develops cures for serious human genetic diseases using CRISPR-CAS9 for Hemoglobinopathies, cancer, and regenerative medicine. Its solution translates CRISPR-Cas9, a gene-editing technology into transformative medicines.
- Dec 2023Post IPO—
- Apr 2021Post IPO$900M
- Dec 2020Post IPO—
- Apr 2020Post IPO$1M
#6
Acquired · Basel, Basel Stadt · founded 2000 · 501 employees$250Mraised▾
Developer of technologies and sustainable farming practices for farmers. It offers crop protection products for keeping plants safe from planting to harvesting, high-technology seeds help mitigate risks such as disease, insect, and climate pressures. It also provides biologicals and digital farming solutions that support regenerative agriculture and soil health.
- May 2023Grant (prize money)$228.7K
- Nov 2022Grant (prize money)$150.5K
- Mar 2021Grant (prize money)$338.7K
- Jan 2021Grant (prize money)$152.3K
#7
Series A · Hombrechtikon, Zurich · founded 2018 · 11 employees$3.7Mraised▾
Provides functional cancer profiling using biomarker analysis. Its assay platform uses biomarkers and genetic profiles and provides information about the best possible proximation of the patient’s response from multiple therapeutic options. It helps a physician for choosing effective therapy for cancer treatment. Its offering is an analysis of biomarkers and genetic profiles for precision medicine.
- Dec 2024Series A—
- Oct 2022Seed$1.3M
- Apr 2021Seed$2.4M
#8
Series A · Zurich, Zurich · founded 2017 · 16 employees$55.8Mraised▾
TOLREMO therapeutics is a developer of small molecules that target novel drug resistance pathways involved in cancer. The company has developed a screening platform for developing novel anti-drug resistance cancer drugs, and is also exploring the possibility of combining existing drugs to prevent drug resistance in cancer.
- Sep 2023Series A$39M
- Jun 2020Series A$4.9M
- Sep 2018Series A$9.4M
- Sep 2017Seed$2.5M
#9
Series A · Lucerne, Lucerne · founded 2017 · 28 employees$20.3Mraised▾
Artificial intelligence (AI) based single-cell data analysis for novel biomarker discovery. The company is developing AI software for single-cell data analysis to discover novel biomarkers for the early and precise detection of a wide range of complex diseases. This AI-based single-cell technology can also be used for the identification of relevant single-cell patterns from mass cytometry data.
- Dec 2023Series A$8M
- Sep 2022Series A$6.2M
- Jan 2022Series A—
- Aug 2020Seed—
#10
Series D · Zurich, Zurich · founded 1997 · 17 employees$47.1Mraised▾
Provider of a platform for genomic data analysis and management. The company is developing software based on gene sequencing which is used in agriculture, bio-banks, clinics, and biopharma research. The company's genomic data management platform enables data integration, secure analysis, and interpretation of molecular and clinical information.
- Jan 2023Grant (prize money)$318.2K
- Nov 2022Series D$20.2M
- Dec 2019Series C$15.3M
- May 2017Series B$10M
#11
Seed · Epalinges, Vaud · founded 2022$50Mraised▾
Provider of engineered cell lines for drug development. It offers DNA-based platform for the production of recombinant adeno-associated virus (rAAV) vectors, human and mammalian cell lines to produce advanced therapy medicinal products.
- May 2023Seed$50M
#12
Series A · Schlieren, Zurich · founded 2016 · 38 employees$60.4Mraised▾
Developer of next-generation non-viral gene therapies. It is a provider of novel enzymatic DNA synthesis tools and technologies for cell and gene therapy applications. It is developing DNA-based vectors by using proprietary drug delivery technology platform Hybridosome which involved engineering extracellular vesicles and exosomes to deliver drugs.
- Sep 2021Series A$60.4M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in Switzerland
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 867 Switzerland-affiliated papers.
- ETH Zurich128
- SIB Swiss Institute of Bioinformatics94
- University of Zurich79
- University of Lausanne63
- University of Bern62
- Gene3→33
- Genome4→32
- Identification (biology)2→16
- Population1→12
- Sequence (biology)1→11
- Gene1→17
- Transcriptome2→11
- Genome2→7
- Proteome1→6
- Phylogenetic tree1→5
- Disease12
- Clinical trial10
- Computational biology7
- MEDLINE6
- Immune system5
Where bioinformatics is researched across Switzerland
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.